Welcome to the international HTA database

Showing [23748 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivosidenib (cholangiocarcinoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Ontario Health	Carrier screening programs for cystic fibrosis, fragile X syndrome, hemoglobinopathies and thalassemia, and spinal muscular atrophy
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V]
2023	NIHR Health Technology Assessment programme	Tonsillectomy compared with conservative management in patients over 16 years with recurrent sore throat: the NATTINA RCT and economic evaluation
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis, 1 to < 2 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book V]
2023	NIHR Health Technology Assessment programme	A multifaceted intervention to reduce antibiotic prescribing among CHIldren with acute COugh and respiratory tract infection: the CHICO cluster RCT
2023	Scottish Health Technologies Group (SHTG)	Tumour profiling tests to guide chemotherapy decisions in early breast cancer
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V]
2023	Scottish Health Technologies Group (SHTG)	Community based respiratory care services for patients with chronic respiratory conditions
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Electromagnetic Navigation Bronchoscopy: Use in Dying for Lung Nodules Resection. Horizon Scanning Technologies]
2023	Scottish Health Technologies Group (SHTG)	Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Robotic Bronchoscopy for Lung Nodule Diagnostics. Horizon Scanning Technologies]
2023	Scottish Health Technologies Group (SHTG)	The clinical effectiveness and cost effectiveness of a digital type 2 diabetes remission programme
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evaluation of invitation letters and information for insured persons on colorectal cancer screening]
2023	Andalusian Health Technology Assessment Area (AETSA)	[Clinical effectiveness and safety of newborn screening for spinal muscular atrophy. Systematic review]
2023	Scottish Health Technologies Group (SHTG)	The cost-effectiveness of the Scottish Hip Fracture Audit
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 \| A23-31]
2023	The Danish Health Technology Council (DHTC)	[Use of artificial intelligence as clinical decision-support in colonoscopy for the diagnosis of neoplastic disease]
2023	Scottish Health Technologies Group (SHTG)	Outpatient parenteral antimicrobial therapy (OPAT) cost calculator
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31]
2023	Center for Drug Evaluation (CDE)	[Latest trend in consumption and utilization of schedule I and II controlled drugs - a nationwide population-based data in Taiwan
2023	NIHR Health Technology Assessment programme	One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT
2023	Scottish Health Technologies Group (SHTG)	Placental growth factor (PlGF)-based testing to help diagnose suspected preterm pre-eclampsia
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Durvalumab (malignant biliary tract cancer [BTC]) – Addendum to Commission A23-26]
2023	Haute Autorite de sante (HAS)	[Assessment of the exhaled nitric oxide measurement for asthma management]
2023	National Institute for Health and Care Excellence (NICE)	AposHealth for knee osteoarthritis. NICE medical technologies guidance 76
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023	Scottish Health Technologies Group (SHTG)	An assessment of the Feeling Good app
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dupilumab (prurigo nodularis) – Addendum to Project A23-24]
2023	Scottish Health Technologies Group (SHTG)	Consideration of selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma (liver cancer)
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darolutamide (prostate cancer) - Addendum to Commission A23-21]
2023	Scottish Health Technologies Group (SHTG)	Store-and-forward teledermatology for triage of primary care referrals
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Esketamine (treatment-resistant major depressive disorder) – Addendum to Commission A23-18]
2023	Scottish Health Technologies Group (SHTG)	Orthotic bracing for the treatment of idiopathic scoliosis in children and young people (less than 18 years)
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (non-transfusion-dependent beta-thalassaemia) - Addendum to Commission A23-20]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V]
2023	Swiss Federal Office of Public Health (FOPH)	Oral anticoagulants for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
2023	Haute Autorite de sante (HAS)	[Assessment of the Endotest® saliva test in complex endometriosis diagnosis situations]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy –Third addendum to Commission E16-03]
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Evaluation of taking mifepristone at home during a medical abortion]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concept for routine practice data collection for valoctocogene roxaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version1.0) – Second addendum to Commission A22-20]
2023	Haute Autorite de sante (HAS)	[2023 update: clinical utility of genomic signatures in early-stage HR-positive/HER2-negative breast cancer]
2023	NIHR Public Health Research (PHR) programme	Behavioural intervention to reduce sexually transmitted infections in people aged 16–24 years in the UK: the safetxt RCT
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: effectiveness of rehabilitation models and approaches for young people with adjustment problems]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V]
2023	Swiss Federal Office of Public Health (FOPH)	Folate tests for suspected folate deficiency
2023	NIHR Health Technology Assessment programme	A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial
2023	Agency for Healthcare Research and Quality (AHRQ)	Efficacy of dental services for reducing adverse events in those receiving chemotherapy for cancer
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V]
2023	Agency for Healthcare Research and Quality (AHRQ)	Efficacy of dental services for reducing adverse events in those undergoing insertion of implantable cardiovascular devices
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V]
2023	Swiss Federal Office of Public Health (FOPH)	Revascularisation versus optimal medical therapy (OMT) for the treatment of chronic coronary syndrome (CCS)
2023	Health Information and Quality Authority (HIQA)	Review of national public health strategies in selected countries
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V]
2023	Swiss Federal Office of Public Health (FOPH)	Calcitonin gene-related peptide antagonists for the prevention of migraine
2023	Canary Health Service	[Conduction system pacing implantation through electroanatomical mapping-guided vs. fluoroscopy]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma in adolescents, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Riociguat (pulmonary arterial hypertension in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Secukinumab (hidradenitis suppurativa) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ravulizumab (neuromyelitis optica spectrum disorder [NMOSD]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Burnout: Can yoga help cope?]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the update of the DMP “Coronary heart disease”]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Routine practice data collection for risdiplam acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version1.0) – Second addendum to Commission A21-131]
2023	Agency for Healthcare Research and Quality (AHRQ)	Living systematic review on cannabis and other plant-based treatments for chronic pain
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the update of the DMP “Depression”]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: wound care-assessment, management, and optimal treatment use]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: gene panel for the identification of myeloid mutations by NGS ‒ evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2023	Health Sciences Institute in Aragon (IACS)	[Incorporation of expanded genetic analysis to assist the assessment of venous thromboembolism risks and recurrent spontaneous miscarriages]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ciltacabtagene autoleucel (relapsing/ refractory multiple myeloma, after at least 3 prior therapies)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Belantamab mafodotin (reassessment after the deadline: multiple myeloma, at least 4 prior therapies, monotherapy)]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Computerized clinical decision support systems for decision support in patients with breast, lung, colorectal or prostate cancer]
2023	Health Technology Wales (HTW)	Renal denervation to treat people with resistant hypertension
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Assessment of the volume-result relationship in specialized care of pediatric cancer]
2023	NIHR Health Technology Assessment programme	Impact of multiparametric MRI on staging and management of patients with suspected or confirmed ovarian cancer Short title: MR in Ovarian Cancer (MROC study)
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Etranacogene dezaparvovec (haemophilia B)]
2023	Scottish Health Technologies Group (SHTG)	Bacteriophage therapy for patients with difficult to treat bacterial infections
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Update: Clinical risk prediction tools for venous thromboembolism in medical patients
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tralokinumab (moderate-to-severe atopic dermatitis in adolescents) - Benefit assessment according to § 35a Social Code Book V]
2023	NIHR Health Technology Assessment programme	Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial
2023	Agency for Healthcare Research and Quality (AHRQ)	Management of postpartum hypertensive disorders of pregnancy
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevance of adding the HbS/E, HbE/E and HbE/β-thal variants to the primary targets of the neonatal screening test for hemoglobinopathies]
2023	NIHR Health Services and Delivery Research programme	Involving carer advisors in evidence synthesis to improve carers’ mental health during end-of-life home care: co-production during COVID-19 remote working
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fenfluramine (new therapeutic indication: Lennox-Gastaut syndrome, add-on therapy, ≥ 2 years)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Clopidogrel, prasugrel, and ticagrelor for the prevention of atherothrombotic events in acute coronary syndrome]
2023	Health Information and Quality Authority (HIQA)	Overview of multiplex antigen near-patient tests for acute respiratory infections
2023	National Institute for Health and Care Excellence (NICE)	Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. NICE technology appraisal guidance 855
2023	Belgian Health Care Knowledge Centre (KCE)	Evaluation of digital medical technologies
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olopatadine/mometasone (allergic rhinitis) - Benefit assessment according to §35a Social Code Book V]
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Emergency department overcrowding in Canada: an update
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Lonapegsomatropin (growth failure due to growth hormone deficiency, ≥ 3 to < 18 years)]
2023	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 856